Europe’s CHMP Okays Xtandi, Erivedge And Spedra, But Rejects Xeljanz
This article was originally published in The Pink Sheet Daily
Two new cancer therapies – Astellas’ prostate cancer drug Xtandi and Roche’s basal cell carcinoma drug Erivedge – have been cleared for European approval by the CHMP scientific advisory panel. It also backed Vivus’ erectile dysfunction therapy Spedra and Avanir’s emotional outburst therapy, Nuedextra, but turned down Pfizer’s JAK inhibitor Xeljanz.
You may also be interested in...
Early Discount Makes Rejection of Astellas’ Xtandi Too Difficult For NICE
By offering an early discount and providing clear clinical effectiveness evidence, Astellas Pharma has propelled its prostate cancer drug Xtandi through U.K.’s NICE.
U.S. Biotechs Strike Out Across Europe
U.S. biotech companies are showing greater interest in building commercial infrastructure in Europe, in order to bring new medicines to European customers without local partners. Switzerland is a popular location, because of its position in the center of the continent, but the presence of experienced management is also important.
Curis Funds Internal Development With Further Erivedge Milestones
The cancer biotech is making strides with its internal pipeline as it continues to earn royalties and collect milestones on its partnered programs.